Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bioftal
- Development stage
- Unknown
- Lead developer
- Laboratorios Lafedar
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**Bioftal** is a marketed Lafedar ophthalmic fixed-dose combination containing chloramphenicol, neomycin sulfate, and phenylephrine hydrochloride. Chloramphenicol and neomycin provide topical antibacterial activity through inhibition of bacterial protein synthesis, while phenylephrine is an alpha-1 adrenergic agonist that produces local vasoconstriction and can reduce ocular redness. Lafedar lists the product as an ophthalmic solution containing chloramphenicol 0.5 g, neomycin sulfate 0.5 g, and phenylephrine hydrochloride 0.125 g per 100 mL.
- Brand names
- Bioftal
02
Targets
ADRA1A (α1A)Bacterial RibosomeBacterial 50S ribosomal subunit
Beyond the preview
Go deeper on Bioftal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioftal.